Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/90900
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium |
Author: | Bosetti, C. Rosato, V. Li, D. Silverman, D. Petersen, G. Bracci, P. Neale, R. Muscat, J. Anderson, K. Gallinger, S. Olson, S. Miller, A. Bueno-de-Mesquita, H. Scelo, G. Janout, V. Holcatova, I. Lagiou, P. Serraino, D. Lucenteforte, E. Fabianova, E. et al. |
Citation: | Annals of Oncology, 2014; 25(10):2065-2072 |
Publisher: | Oxford University Press (OUP) |
Issue Date: | 2014 |
ISSN: | 1569-8041 1569-8041 |
Statement of Responsibility: | C. Bosetti ... P. A. Baghurst ... et al. |
Abstract: | BACKGROUND: Type 2 diabetes mellitus has been associated with an excess risk of pancreatic cancer, but the magnitude of the risk and the time-risk relationship are unclear, and there is limited information on the role of antidiabetic medications. PATIENTS AND METHODS: We analyzed individual-level data from 15 case-control studies within the Pancreatic Cancer Case-Control Consortium, including 8305 cases and 13 987 controls. Pooled odds ratios (ORs) were estimated from multiple logistic regression models, adjusted for relevant covariates. RESULTS: Overall, 1155 (15%) cases and 1087 (8%) controls reported a diagnosis of diabetes 2 or more years before cancer diagnosis (or interview, for controls), corresponding to an OR of 1.90 (95% confidence interval, CI, 1.72-2.09). Consistent risk estimates were observed across strata of selected covariates, including body mass index and tobacco smoking. Pancreatic cancer risk decreased with duration of diabetes, but a significant excess risk was still evident 20 or more years after diabetes diagnosis (OR 1.30, 95% CI 1.03-1.63). Among diabetics, long duration of oral antidiabetic use was associated with a decreased pancreatic cancer risk (OR 0.31, 95% CI 0.14-0.69, for ≥15 years). Conversely, insulin use was associated with a pancreatic cancer risk in the short term (OR 5.60, 95% CI 3.75-8.35, for <5 years), but not for longer duration of use (OR 0.95, 95% CI 0.53-1.70, for ≥15 years). CONCLUSION: This study provides the most definitive quantification to date of an excess risk of pancreatic cancer among diabetics. It also shows that a 30% excess risk persists for more than two decades after diabetes diagnosis, thus supporting a causal role of diabetes in pancreatic cancer. Oral antidiabetics may decrease the risk of pancreatic cancer, whereas insulin showed an inconsistent duration-risk relationship. |
Keywords: | case–control study diabetes insulin oral antidiabetics pancreatic cancer pooled analysis |
Rights: | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com |
DOI: | 10.1093/annonc/mdu276 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/442302 |
Published version: | http://dx.doi.org/10.1093/annonc/mdu276 |
Appears in Collections: | Aurora harvest 7 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.